MerLion Pharmaceuticals is dedicated to developing innovative antibiotics to address the growing challenge of bacterial infections, particularly those caused by antibiotic-resistant strains. The company's lead product, finafloxacin, is a next-generation fluoroquinolone antibiotic known for its unique properties, including rapid action and a strong safety profile. Finafloxacin has undergone extensive clinical trials, demonstrating efficacy in treating various infections, including acute otitis externa (AOE) and complicated urinary tract infections (cUTIs). The drug has received approval from the US FDA and Health Canada for the treatment of AOE, and it is being explored for additional applications, including as a medical countermeasure against biothreat agents.

In addition to its focus on human health, MerLion Pharmaceuticals is collaborating with the UK Defence Science and Technology Laboratory on projects funded by the US Defense Threat Reduction Agency. This partnership aims to investigate the potential of finafloxacin against pathogens that pose bioweapon threats. The company is committed to advancing its research and development efforts to provide effective solutions for life-threatening infections, thereby contributing to the global fight against antibiotic resistance and enhancing public health safety.

Germany

MerLion Pharmaceuticals - We are a bio-pharmaceutical company focused on the development of novel antibiotics to combat the evolving threat of bacterial infections in humans and animals.

MerLion Pharmaceuticals is located in Berlin-Buch, Germany and manages the non-clinical and clinical development as well as active pharmaceutical ingredient and drug product development and manufacturing. 

Our pipeline includes the antibiotics finafloxacin and friulimicin.

MerLion Pharmaceuticals

Company Details